ClinicalTrials.gg
CompletedNCT05815680Updated Nov 14, 2023

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

A Phase 1 interventional study of metformin and digoxin in Overweight Subjects and Obese Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-14.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing mazdutide in Overweight — 7 open to participants now, 8 under way, 3 of them phase 3. mazdutide · Overweight.

Enrollment
13th of 15
48 · median 180
Started
2023
with 2 others
Phase 1
3 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
8 of 15
Innovent Biologics (Suzhou) Co. Ltd.

Among the 15 studies testing mazdutide in Overweight, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 1, and was the 6th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

7 of the 15 studies testing mazdutide in Overweight are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing mazdutide in Overweight, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

03

Conditions studied

  • Overweight Subjects
  • Obese Subjects

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, age between 18 and 45 years (both inclusive) at the time of signing
  • (BMI) between 24 and 30 kg/m\^2 (both inclusive) and weight≥50kg
  • The subject has no birth plan and voluntarily takes effective measures within 6 months after signing the informed consent form to the last medication

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular, respiratory, hepatic, digestive (including digestive diseases that significantly affect gastric emptying or gastric motility, such as severe gastric spasticity or pyloric stenosis), endocrine (including but not limited to history of thyroid cancer or precancerous lesions), hematological and neurological disorders, or muscle degenerative disorders
  • Drug or alcohol abuse
  • Have dysphagia or any history of gastrointestinal diseases that affect drug absorption.
  • Medical history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Have a history of acute and chronic pancreatitis or serum amylase and/or lipase ≥ value (Upper Limit of Normal value, ULN) at the time of screening.
  • Those with a history of hypoglycemia.
  • Previous or current mental illness.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    warfarin+atorvastatin+IBI362

    Drug: IBI362 · Drug: warfarin · Drug: atorvastatin

  • Experimental
    metformin+digoxin+IBI362

    Drug: metformin · Drug: digoxin · Drug: IBI362

Interventions

  • For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

  • For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

  • DrugIBI362

    Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.

  • For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

  • For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

06

What researchers measure

Primary outcomes

  1. Maximum observed metformin plasma concentration at steady state

    Time frame: up to 116 days

  2. Area under the metformin plasma concentration-time curve

    Time frame: up to 116 days

  3. Maximum observed warfarin plasma concentration at steady state

    Time frame: up to 116 days

  4. Area under the warfarin plasma concentration-time curve

    Time frame: up to 116 days

  5. Maximum observed atorvastatin plasma concentration at steady state

    Time frame: up to 116 days

  6. Area under the atorvastatin plasma concentration-time curve

    Time frame: up to 116 days

  7. Maximum observed digoxin plasma concentration at steady state

    Time frame: up to 116 days

  8. Area under the digoxin plasma concentration-time curve

    Time frame: up to 116 days

Secondary outcomes

  1. Actual adverse events

    Time frame: up to 116 days

  2. Terminal elimination half-life

    Time frame: up to 116 days

  3. time to maximum plasma concentration of IBI362

    Time frame: up to 116 days

  4. Incremental area under the INR (international normalised ratio) -curve of warfarin

    Time frame: up to 116 days

  5. Total apparent clearance of IBI362

    Time frame: up to 116 days

  6. Apparent volume of distribution of IBI362

    Time frame: up to 116 days

07

Study locations

1 site
  • Aerospace Center Hospital
    Beijing, Beijing 100049, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2023, 4 months.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 18, 2023
StartActual
Apr 6, 2023
Primary completionActual
Aug 18, 2023
CompletionActual
Oct 30, 2023
Last update
Nov 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05815680
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 6, 2023
Primary completion
Aug 18, 2023
Completion
Oct 30, 2023
Last update
Nov 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mazdutide · Atorvastatin

Start the discussion